29 - References

References

520 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 4 References

1. Scott G, et  al. Patients’ perceptions of self-­administered dosing to opioid agonist treatment and other changes during the COVID-­19 ­pandemic: a qualitative study. BMJ Open 2023; 13:e069857.
2. Adams KK, et al. Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. Addict Sci Clin Pract 2021; 16:36.
3. Lewer D, et al. Fatal opioid overdoses during and shortly after hospital admissions in England: a case-­crossover study. PLoS Med 2021; 18:e1003759.
4. Strang J, et al. Naloxone without the needle – systematic review of candidate routes for non-­injectable naloxone for opioid overdose reversal. Drug Alcohol Depend 2016; 163:16–23.
5. Amaducci A, et al. Naloxone use in novel potent opioid and fentanyl overdoses in emergency department patients. JAMA Netw Open 2023; 6:e2331264.
6. Van Dorp E, et al. Naloxone reversal of buprenorphine-­induced respiratory depression. Anesthesiology 2006; 105:51–57.
7. World Health Organization. Community management of opioid overdose. 2014; http://www.who.int/substance_abuse/publications/ management_opioid_overdose/en.
8. Department of Health and Social Care. Drug misuse and dependence: UK guidelines on clinical management. 2017; https://www.gov.uk/ government/publications/drug-­misuse-­and-­dependence-­uk-­guidelines-­on-­clinical-­management.
9. McDonald R, et  al. Take-­home naloxone kits: attitudes and likelihood-­of-­use outcomes from a European survey of potential overdose ­witnesses. Eur Addict Res 2022; 28:220–225.
10. Harris M. Normalised pain and severe health care delay among people who inject drugs in London: adapting cultural safety principles to promote care. Soc Sci Med 2020; 260:113183.
11. National Institute for Health and Care Excellence. Coexisting severe mental illness and substance misuse: community health and social care services. NICE Guideline [NG58]. 2016 (last accessed August 2024); https://www.nice.org.uk/guidance/ng58.
12. Tompkins DA, et al. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther 2014; 348:217–226.
13. San L, et  al. Assessment and management of opioid withdrawal symptoms in buprenorphine-­dependent subjects. Br J Addict 1992; 87:55–62.
14. Dunn KE, et  al. Characterizing opioid withdrawal during double-­blind buprenorphine detoxification. Drug Alcohol Depend 2015; 151:47–55.
15. Melichar J, et al. Abstract: Dramatically improved detoxification outcomes using long-­acting injectable buprenorphine (LAIB) in the UK’s first shared-­care GP-­led LAIB service. J Psychopharm 2023; 37 Suppl.
16. Tompkins DA, et al. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-­item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend 2009; 105:154–159.
17. Handelsman L, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13:293–308.
18. National Institute for Health and Care Excellence. Methadone and buprenorphine for the management of opioid dependence. Technology appraisal [TA114]. 2007 (reviewed February 2016, last accessed August 2024); https://www.nice.org.uk/guidance/ta114.
19. Farrell M. Opiate withdrawal. Addiction 1994; 89:1471–1475.
20. Fudala PJ, et al. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-­day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47:525–534.
21. Larney S, et al. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17. Addiction 2023; 118:1527–1539.
22. Sordo L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-­analysis of cohort studies. BMJ 2017; 357:j1550.
23. Aldabergenov D, et al. Methadone and buprenorphine-­related deaths among people prescribed and not prescribed opioid agonist therapy during the COVID-­19 pandemic in England. Int J Drug Policy 2022; 110:103877.
24. D’Onofrio G, et al. Incidence of precipitated withdrawal during a multisite emergency department-­initiated buprenorphine clinical trial in the era of fentanyl. JAMA Netw Open 2023; 6:e236108.
25. Klimas J, et al. Retention in opioid agonist treatment: a rapid review and meta-­analysis comparing observational studies and randomized controlled trials. Syst Rev 2021; 10:216.
26. Treece JM, et al. Comprehensive review on methadone-­induced QT prolongation and torsades. J Pharmacol Pharmacother 2018; 9:66–75.
27. Vierke C, et al. Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy. Eur Arch Psychiatry Clin Neurosci 2021; 271:847–856.
28. Madden K, et al. Clinically significant drug-­drug interaction between methadone and cannabidiol. Pediatrics 2020; 145:e20193256.
29. McCance-­Katz EF, et al. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19:4–16.
30. Jones HE, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320–2331.
31. Winstock AR, et al. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Subst Use Misuse 2010; 45:240–252.
32. Winstock AR, et al. What is diversion of supervised buprenorphine and how common is it? J Addict Dis 2009; 28:269–278.
33. Leslie ST, et al. Methadone: evidence of accumulation. BMJ 1977; 1:1284.
34. Verebely K, et al. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975; 18:180–190.

Addictions and substance misuse CHAPTER 4 35. White JM, et al. Mechanisms of fatal opioid overdose. Addiction 1999; 94:961–972. 36. Farrell M, et al. Suicide and overdose among opiate addicts. Addiction 1996; 91:321–323. 37. Abrahamsson T, et al. Benzodiazepine, z-­drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment – a nation-­wide register-­based open cohort study. Drug Alcohol Depend 2017; 174:58–64. 38. Pierce M, et al. Impact of treatment for opioid dependence on fatal drug-­related poisoning: a national cohort study in England. Addiction 2016; 111:298–308. 39. Macleod J, et al. Prescription of benzodiazepines, z-­drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med 2019; 16:e1002965. 40. Ključević Ž, et al. Liver damage indices as a tool for modifying methadone maintenance treatment: a cross-­sectional study. Croat Med J 2018; 59:298–306. 41. Odoma VA, et al. Opioid prescription in patients with chronic kidney disease: a systematic review of comparing safety and efficacy of opioid use in chronic kidney disease patients. Cureus 2023; 15:e45485. 42. Krantz MJ, et al. Torsade de pointes associated with very-­high-­dose methadone. Ann Intern Med 2002; 137:501–504. 43. Kornick CA, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105:499–506. 44. Martell BA, et al. The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med 2003; 139:154–155. 45. Pani PP, et al. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. Cochrane Database Syst Rev 2013; 6:CD008939. 46. Mayet S, et al. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug Alcohol Rev 2011; 30:388–396. 47. Hancox JC, et al. Synthetic cannabinoids and potential cardiac arrhythmia risk: an important message for drug users. Ther Adv Drug Saf 2020; 11:2042098620913416. 48. Isbister GK, et al. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol 2013; 76:48–57. 49. Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2:CD002207. 50. Gov.UK. From harm to hope: a 10-­year drugs plan to cut crime and save lives. First Annual Report 2022-­23. 2023 (last assessed August 2024); https://assets.publishing.service.gov.uk/media/65dc7655529bfa0011e95508/E02949325_15.109_HO_Harm_to_Hope_AR_2022-­ 23_Web+Accessible_v02.pdf. 51. Lintzeris N, et al. The uptake of long-­acting depot buprenorphine for treating opioid dependence in Australia, 2019-­2022: longitudinal sales data analysis. Med J Aust 2024; 220:339–340. 52. Walsh SL, et al. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274:361–372. 53. Bickel WK, et al. Buprenorphine: dose-­related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988; 247:47–53. 54. Marsch LA, et al. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend 2005; 77:195–204. 55. Edinoff AN, et al. Low-­dose initiation of buprenorphine: a narrative review. Curr Pain Headache Rep 2023; 27:175–181. 56. Marsden J, et al. Extended-­release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-­label randomised controlled trial of the effectiveness and cost-­effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone. Trials 2022; 23:697. 57. Boyett B, et  al. Continued posttrial benefits of buprenorphine extended release: RECOVER study findings. J Addict Med 2023; 17:182–189. 58. Lintzeris N, et al. Strategies for transfer from methadone to buprenorphine for treatment of opioid use disorders and associated outcomes: a systematic review. J Addict Med 2022; 16:143–151. 59. Omoigui S, et al. Use of ketamine in ameliorating opioid withdrawal symptoms during an induction phase of buprenorphine. Open Pain J 2011; 4:1–3. 60. Hämmig R, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil 2016; 7:99–105. 61. Oakley B, et al. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. Drug Alcohol Rev 2021; 40:567–571. 62. Tay Wee Teck J, et al. Using microdosing to induct patients into a long-­acting injectable buprenorphine depot medication in low threshold community settings: a case study. Front Pharmacol 2021; 12:631784. 63. Tang VM, et al. Case series: limited opioid withdrawal with use of transdermal buprenorphine to bridge to sublingual buprenorphine in hospitalized patients. Am J Addict 2020; 29:73–76. 64. Terasaki D, et al. Transitioning hospitalized patients with opioid use disorder from methadone to buprenorphine without a period of opioid abstinence using a microdosing protocol. Pharmacotherapy 2019; 39:1023–1029. 65. Weimer MB, et al. Hospital-­based buprenorphine micro-­dose initiation. J Addict Med 2021; 15:255–257. 66. Bhatraju EP, et al. Low dose buprenorphine induction with full agonist overlap in hospitalized patients with opioid use disorder: a retrospective cohort study. J Addict Med 2022; 16:461–465. 67. Anderson C, et al. Transitioning from high-­dose methadone to buprenorphine using a microdosing approach: unique considerations at ASAM level 3 facilities. J Addict Med 2023; 17:241–244. 68. Nielsen S, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016; 5:CD011117.

522 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 4 69. Amass L, et al. Alternate-­day buprenorphine dosing is preferred to daily dosing by opioid-­dependent humans. Psychopharmacology 1998; 136:217–225. 70. Kothadia JP, et al. Acute hepatitis after oral buprenorphine use in a heroin addict: 1838. Am J Gastroenterol 2016; 111:S881. 71. Berson A, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001; 34:346–350. 72. Comer SD, et al. Abuse liability of prescription opioids compared to heroin in morphine-­maintained heroin abusers. Neuropsychopharmacology 2008; 33:1179–1191. 73. Hickman M, et  al. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction 2018; 113:1461–1476. 74. Sarton E, et  al. Naloxone reversal of opioid-­induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Med Biol 2008; 605:486–491. 75. Ferri M, et al. Slow-­release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev 2013; 6:CD009879. 76. Strang J, et  al. Heroin on trial: systematic review and meta-­analysis of randomised trials of diamorphine-­prescribing as treatment for ­refractory heroin addictiondagger. Br J Psychiatry 2015; 207:5–14. 77. Byford S, et al. Cost-­effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry 2013; 203:341–349. 78. Strang J, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375:1885–1895. 79. Lingford-­Hughes AR, et al. BAP updated guidelines: evidence-­based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012; 26:899–952. 80. Kalk NJ, et al. Fatalities associated with gabapentinoids in England (2004–2020). Br J Clin Pharmacol 2022; 88:3911–3917. 81. Bonnet U, et al. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 2017; 27:1185–1215. 82. James PD, et al. Non-­medical use of olanzapine by people on methadone treatment. BJPsych Bull 2016; 40:314–317. 83. Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis 2008; 27:49–65. 84. Nunes EV, et al. Treatment of co-­occurring depression and substance dependence: using meta-­analysis to guide clinical recommendations. Psychiatr Ann 2008; 38:nihpa128505. 85. Taylor D, et al. The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use. Ther Adv Psychopharmacol 2024; 14:20451253241243297. 86. National Institute for Heath and Care Excellence. Drug misuse in over 16s: opioid detoxification. Clinical guideline [CG52]. 2007 (checked January 2019, last accessed August 2024; updated 2007); https://www.nice.org.uk/guidance/cg52. 87. National Institute for Health and Care Excellence. Drug misuse in over 16s: psychosocial interventions. Clinical guideline [CG51]. 2007 (last checked July 2016, last accessed August 2024; updated 2007); https://www.nice.org.uk/guidance/cg51. 88. Nosyk B, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-­based retrospective cohort study. Addiction 2012; 107:1621–1629. 89. Minozzi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; 4:CD001333. 90. Lobmaier P, et al. Sustained-­release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; 2:CD006140. 91. National Institute for Health and Care Excellence. Naltrexone for the management of opioid dependence. Technology apprasial [TA115]. 2007 (last reviewed November 2010, last checked August 2024); https://www.nice.org.uk/guidance/ta115. 92. Degenhardt L, et al. Excess mortality among opioid-­using patients treated with oral naltrexone in Australia. Drug Alcohol Rev 2015; 34:90–96. 93. Darke S, et al. Circumstances of death of opioid users being treated with naltrexone. Addiction 2019; 114:2000–2007. 94. Latif ZE, et  al. Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-­release naltrexone vs buprenorphine-­naloxone: a randomized clinical trial and follow-­up study. JAMA Psychiatry 2019; 76:127–134. 95. Dean AJ, et al. Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci 2006; 31:38–45. 96. Carroll KM, et al. Accounting for the uncounted: physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug Alcohol Depend 2018; 192:264–270. 97. British Pain Society, et al. Pain and substance misuse: improving the patient experience. A consensus statement prepared by The British Pain Society in collaboration with The Royal College of Psychiatrists, The Royal College of General Practitioners and The Advisory Council on the Misuse of Drugs. 2007 (updated 2007); https://www.britishpainsociety.org/static/uploads/resources/misuse_0307_v13_FINAL.pdf. 98. Goel A, et al. Perioperative Pain and Addiction Interdisciplinary Network (PAIN): protocol of a practice advisory for the perioperative ­management of buprenorphine using a modified Delphi process. BMJ Open 2019; 9:e027374. 99. Goverment of Western Australia. Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. 2024; https://www.mhc.wa.gov.au/media/4919/mhc24-­32319-­cpop-­clinical-­guidelines-­for-­the-­use-­of-­depot-­buprenorphine-­in-­ the-­treatment-­of-­opioid-­dependence-­march-­2024.pdf. 100. Shelton T, et al. Case report. Successful induction of buprenorphine in medically complex patients concurrently on opioids: a case series at a tertiary care center. Front Pharmacol 2024; 15:1335345. 101. DeWeese JP, et al. Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: titration, implementation barriers, and strategies to overcomes. Subst Abus 2021; 42:506–511. 102. Lyndon A, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction 2017; 112:1580–1589.